Enterprise Investor Jason Green Talks SPAC Hopefuls Versus Traditional IPOs: TechCrunch

This circular scenario revolves around a drugmaker called Roivant Sciences, which wants to merge with a SPAC and then take over a SPAC that acquired Immunovant from Roivant less than two years ago, Bloomberg reports.